Silymarin-Mediated Degradation of c-Myc Contributes to the Inhibition of Cell Proliferation in Human Colorectal Cancer Cells
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
In this study, we elucidated the molecular mechanism of silymarin by which silymarin may inhibits cell proliferation in human colorectal cancer cells in order to search the new potential anti-cancer target associated with the cell growth arrest. Silymarin reduced the level of c-Myc protein but not mRNA level indicating that silymarin-mediated downregulation of c-Myc may result from the proteasomal degradation. In the confirmation of silymarin-mediated c-Myc degradation, MG132 as a proteasome inhibitor attenuated c-Myc degradation by silymarin. In addition, silymarin phosphorylated the threonine-58 (Thr58) of c-Myc and the point mutation of Thr58 to alanine blocked its degradation by silymarin, which indicates that Thr58 phosphorylation may be an important modification for silymarin-mediated c-Myc degradation. We observed that the inhibition of ERK1/2, p38 and GSK3β blocked the Thr58 phosphorylation and subsequent c-Myc degradation by silymarin. Finally, the point mutation of Thr58 to alanine attenuated silymarin-mediated inhibition of the cell growth. The results suggest that silymarin induces the cell growth arrest through c-Myc proteasomal degradation via ERK1/2, p38 and GSK3β-dependent Thr58 phosphorylation. Key words – Cancer chemoprevention, Cell growth arrest, c-Myc, Human colorectal cancer, Silymarin
Abstract
In this study, we elucidated the molecular mechanism of silymarin by which silymarin may inhibits cell proliferation in human colorectal cancer cells in order to search the new potential anti-cancer target associated with the cell growth arrest. Silymarin reduced the level of c-Myc protein but not mRNA level indicating that silymarin-mediated downregulation of c-Myc may result from the proteasomal degradation. In the confirmation of silymarin-mediated c-Myc degradation, MG132 as a proteasome inhibitor attenuated c-Myc degradation by silymarin. In addition, silymarin phosphorylated the threonine-58 (Thr58) of c-Myc and the point mutation of Thr58 to alanine blocked its degradation by silymarin, which indicates that Thr58 phosphorylation may be an important modification for silymarin-mediated c-Myc degradation. We observed that the inhibition of ERK1/2, p38 and GSK3β blocked the Thr58 phosphorylation and subsequent c-Myc degradation by silymarin. Finally, the point mutation of Thr58 to alanine attenuated silymarin-mediated inhibition of the cell growth. The results suggest that silymarin induces the cell growth arrest through c-Myc proteasomal degradation via ERK1/2, p38 and GSK3β-dependent Thr58 phosphorylation. Key words – Cancer chemoprevention, Cell growth arrest, c-Myc, Human colorectal cancer, Silymarin
참고문헌 (22)
- Abenavoli, L., "Milk thistle in liver diseases: past, present, future", Phytother. Res, 24, pp.1423~1432 (2010)
- Augenlicht, L. H., "Low-level c-myc amplification in human colonic carcinoma cell lines and tumors: a frequent, p53-independent mutation associated with improved outcome in a randomized multi-institutional trial", Cancer Res, 57, pp.1769~1775 (1997)
- Bretones, G., "Myc and cell cycle control", Biochim. Biophys. Acta, 1849, pp.506~516 (2015)
- Dang, C.V., "MYC on the path to cancer", Cell, 149, pp.22~35 (2012)
- Diehl, J. A., "Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway", Genes Dev, 11, pp.957~972 (1997)
- Draz, E. I., "Neurotrophic and antioxidant effects of silymarin comparable to 4-methylcatechol in protection against gentamicin-induced ototoxicity in guinea pigs", Pharmacol. Rep, 67, pp.317~325 (2015)
- 어현지, "Activating Transcription Factor 3 is a Molecular Target for Apoptotic Effect of Silymarin in Human Colorectal Cancer Cells", 한국자원식물학회지, 29(3), pp.281~288 (2016), 한국자원식물학회[DOI]
- Eo, H. J., "Silymarin induces cyclin D1 proteasomal degradation via its phosphorylation of threonine-286 in human colorectal cancer cells", Int. Immunopharmacol, 24, pp.1~6 (2015)
- Fan, L., "Silymarin induces cell cycle arrest and apoptosis in ovarian cancer cells", Eur. J. Pharmacol, 743, pp.79~88 (2014)
- Fletcher, S., "Small-molecule inhibitors of the Myc oncoprotein", Biochim. Biophys. Acta, 1849, pp.525~543 (2015)
- Gu, M., "Silymarin ameliorates metabolic dysfunction associated with diet-induced obesity via activation of Farnesyl X receptor", Front. Pharmacol, 7, pp.345~ (2016)
- Guo, Y., "Silymarin improved diet-induced liver damage and insulin resistance by decreasing inflammation in mice", Pharm. Biol, 8, pp.1~6 (2016)
- Guo, Z., "Rictor regulates FBXW7-dependent c-Myc and cyclin E degradation in colorectal cancer cells", Biochem. Biophys. Res. Commun, 418, pp.426~432 (2012)
- Jing, H., "A SIRT2-selective inhibitor promotes c-Myc oncoprotein degradation and exhibits broad anticancer activity", Cancer Cell, 29, pp.767~768 (2016)
- Kazazis, C. E., "The therapeutic potential of milk thistle in diabetes", Rev. Diabet. Stud, 11, pp.167~174 (2014)
- Little, C. D., "Amplification and expression of the c-myc oncogene in human lung cancer cell lines", Nature, 306, pp.194~196 (1983)
- Liu, X., "Wang. 2016. Bufalin inhibits pancreatic cancer by inducing cell cycle arrest via the c-Myc", NF-kappaB pathway, 2016, pp.193, 538~545
- Mariani-Costantini, R., "In situ c-myc expression and genomic status of the c-myc locus in infiltrating ductal carcinomas of the breast", Cancer Res, 48, pp.199~205 (1988)
- Mereish, K. A., "Protection against microcystin-LR-induced hepatotoxicity by Silymarin: biochemistry, histopathology, and lethality", Pharm. Res, 8, pp.273~277 (1991)
- Wright, J. B., "Upregulation of c-MYC in cis through a large chromatin loop linked to a cancer risk-associated single-nucleotide polymorphism in colorectal cancer cells", Mol. Cell. Biol, 30, pp.1411~1420 (2010)
- Wu, T., "Silymarin suppressed lung cancer growth in mice via inhibiting myeloid-derived suppressor cells", Biomed. Pharmacother, 81, pp.460~467 (2016)
- Yeh, E., "A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells", Nat. Cell Biol, 6, pp.308~318 (2004)